Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced TNBC patients, but multiple clinical studies...

Full description

Bibliographic Details
Main Authors: HUANG Shifen, LING Xiaoling
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2021-01-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
advanced triple-negative breast cancer
pd-1/pd-l1 inhibitors
angiogenesis inhibitors
Online Access:http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0615.htm

Internet

http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0615.htm

Similar Items